{
  "meta": {
    "generated_at": "2025-12-29T22:57:10.376Z",
    "total_signals": 22,
    "filter": "Strong/Confirmed Signals Only"
  },
  "signals": [
    {
      "ticker": "HONASA.NS",
      "signal": "BUY",
      "price": 277,
      "market": "IN",
      "technical_context": "CE+QQE (Orig SL: 250.96, Orig TP: 355.13)",
      "analysis": {
        "ticker": "HONASA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 85,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal at 277 INR aligns with a 'buy on dip' setup following a strong fundamental turnaround. In Q2 FY26 (reported Nov 2025), Honasa swung to a Net Profit of ₹39.2 Cr (vs a ₹18.5 Cr loss in Q2 FY25) with 16.5% revenue growth, validating the success of last year's 'Project NeEV' distribution overhaul. The stock rallied to ~308 post-earnings and has retraced to 277, finding support near the 50-day moving average. Analyst consensus has shifted positively with targets ranging from 330 to 450 INR.",
        "fundamental_summary": "Honasa Consumer has successfully navigated its distribution model transition (Project NeEV). Q2 FY26 financials show a consolidated PAT of ₹39.2 Cr and EBITDA margin expansion to ~9%. Revenue grew to ₹539 Cr, driven by volume growth and offline expansion. The company has also entered the oral care segment via acquisitions (Fang/Couch Commerce), diversifying its portfolio beyond Mamaearth.",
        "catalysts": [
          "Q2 FY26 Turnaround: Swing to profitability (₹39 Cr Profit vs Loss YoY).",
          "New Acquisitions: Entry into oral care (Fang) and prestige skincare (Luminve).",
          "Analyst Upgrades: Brokerages like Jefferies/ICICI maintain 'Buy' with targets up to 450 INR.",
          "Technical Rebound: 20-day moving average crossover confirmed recently."
        ],
        "tradeSetup": {
          "entryZone": "275 - 280 INR",
          "stopLoss": "250.00 INR (Below recent swing low and psychological support)",
          "targetPrice": "330.00 - 355.00 INR (Near post-earnings high and gap resistance)",
          "riskRewardRatio": "1:2.5"
        },
        "sources": []
      }
    },
    {
      "ticker": "HUDCO.NS",
      "signal": "BUY",
      "price": 226.75,
      "market": "IN",
      "technical_context": "Supertrend Flip (Orig SL: 208.64, Orig TP: 281.09)",
      "analysis": {
        "ticker": "HUDCO.NS",
        "sentiment": "Bullish",
        "confidenceScore": 85,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal is strongly supported by fundamental tailwinds. HUDCO reported robust Q2 FY25 results with Net Profit up ~52% YoY and a 30% expansion in its loan book, driven by record sanctions. The stock trades at a reasonable P/E of ~16x compared to the industry average, offering a margin of safety. The upcoming Union Budget (Feb 1, 2025) acts as a major catalyst, with high expectations for increased allocations to PMAY (affordable housing) and infrastructure spending, sectors where HUDCO is a primary lender. Technical indicators show a breakout from consolidation with strong support near the ₹210 level, validating the Supertrend flip.",
        "fundamental_summary": "In Q2 FY25, HUDCO posted a Net Profit of ₹689 Cr (+52% YoY) and Revenue of ₹2,518 Cr (+35% YoY). The company achieved record loan sanctions of ₹92,985 Cr (+22% YoY) in H1, signalling strong future disbursements. Asset quality remains stable, and its 'Navratna' status grants it operational flexibility. Valuation remains attractive relative to private peers.",
        "catalysts": [
          "Union Budget (Feb 1, 2025) expected to boost affordable housing (PMAY) allocations.",
          "Potential RBI Repo Rate cuts in 2025 reducing borrowing costs.",
          "Record loan book growth and robust sanctions pipeline.",
          "Recent dividend declaration indicating healthy cash flows."
        ],
        "tradeSetup": {
          "entryZone": "226.00 - 228.00",
          "stopLoss": "208.64",
          "targetPrice": "281.00",
          "riskRewardRatio": "1:3"
        },
        "sources": [
          {
            "title": "topstockresearch.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHOz9u-wYY2UfS728lsYfeTAHsTbIsyA2lgf8d6MpDBYVOmfydjRS1ePkM_Qn6hIdBtnbRUNXSDaGR7BTVz2rrGyjjGxbttgxERTLXHqL7ow35VN_nBXLnYyUlMhtmWc_eZXRjeIDzJOVXfBVoNJLERQXqqYiVmAxQ378Dp"
          },
          {
            "title": "tickertape.in",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHRM4kNa1ZgebUlTWrjZy-K278kdjrTMNFVkmFsKnh43KAu6qAuVl3ivgqu_3kR-7PaWNnX9TeMvdhYL2QAfqtTqxdxWcgXvvz-x__kkwaZXJkdPyLB4MbtAbG0HiVShU2CdJVDsy7PBK5zooHXAcujTw7EEuPfyXkcYVtF-SnDsBRxQTjK0ZJfvrg="
          }
        ]
      }
    },
    {
      "ticker": "PTCIL.NS",
      "signal": "BUY",
      "price": 19176,
      "market": "IN",
      "technical_context": "Supertrend Flip (Orig SL: 16931.53, Orig TP: 25909.40)",
      "analysis": {
        "ticker": "PTCIL.NS",
        "sentiment": "Bullish",
        "confidenceScore": 90,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal is strongly supported by fundamental catalysts and sector tailwinds. PTC Industries is a direct beneficiary of India's 'Make in India' defense initiative, evidenced by its recent Q2 FY25 results showing a 113% YoY jump in Net Profit and a 61% YoY increase in EBITDA. The company has secured critical strategic partnerships with Bharat Dynamics (for aero-engines), Honeywell, and BAE Systems, providing long-term revenue visibility. Technically, the stock is in a strong uptrend, outperforming the Sensex, and brokerage ICICI Securities has recently issued a 'Buy' rating with a target of ₹20,070. While the P/E valuation is high, the scarcity of titanium casting capabilities in India justifies the premium.",
        "fundamental_summary": "In Q2 FY25, PTC Industries reported robust growth with Consolidated Total Income up 34% YoY to ₹80.8 Cr and Net Profit surging 113% YoY to ₹17.3 Cr. EBITDA margins expanded significantly to ~36.7%. The company is effectively transitioning from a general engineering firm to a specialized defense and aerospace manufacturer (titanium alloys, aero-engines).",
        "catalysts": [
          "Joint Venture with Bharat Dynamics Ltd to manufacture aero-engines and propulsion systems.",
          "Supply orders from Israel Aerospace Industries and BAE Systems.",
          "Acquisition of Trac Precision Solutions to enhance machining capabilities.",
          "Capacity expansion at the Lucknow Defense Industrial Corridor facility."
        ],
        "tradeSetup": {
          "entryZone": "18,800 - 19,200",
          "stopLoss": "16,930",
          "targetPrice": "22,500 - 25,900",
          "riskRewardRatio": "1:3"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEXv72SX9nJT1tpi7quNgb15EBjeq4VTVvxTQH8xSR6UqE0SdSFHwf2JySicr1UTyti0DNhS0GdK4JyfFi7B_q11tPA7J02HP8Igh0YEfczSub4M3oSf7ftqrjlpGgcr7PVFOMlAUu0ZWFAncGBCqcDCSTR5wBtbAQbrgtws41dYdqUrKNTso86hCuTXBUiyr59Xy01J9P7UtUINAtFFpRk-f6BkUzUswKwz0ZoZX4j2KrQj_kkX0q1bTJ-zFG47jH6"
          },
          {
            "title": "ptcil.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGtvm0jKH1etTwXHRQv3JGULAe_li39OhJ_wr0PwuVbG-3kDSV03Wod51N0IVS8DbGRUxiM40nT7kDlYIsDKTiTOKxS5Tf65WAZbJD5CV0xyQA-yySc61F7E6cg64YUw0LAE0A8fa0W1-f3aN8rvqpXRzK3XgVk7dos2KSyktheKd8T0ZI2EmW9jTo6D2AuEjeWh-wCwe5PE5gjUz5ih34iSmaHCvDYXPm1dptpVMGGtwFAOBF71kU="
          },
          {
            "title": "ptc.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG0OVH3TNQtqhy0SMRlqRDu1YVeTsIU4-GrtG1P9Tcu11XRafK0CirKaA_tYT2wqPtOWDIvh6_Sq4e7KRuMU2NwvT_U3DIl-Y2iL7gbken5hUjl83IJx6wG0pzeWdHgsgP3F3hUkVm8PXv1Efem_MtINyPhFA=="
          },
          {
            "title": "investing.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH48vQvljAqdJEu6LC9Z9MfKoj0Ev1EqPn-HbRd9S7m_j7Pj7euPd-uz91BRJfp2GIbcKR7UTbCWHUu9D0AIbC_E8G3udAgCWP1hfW3mqrqQo3p05PKHnqDUSFLLcAsEbzRW2fWnSS8-SYDTMd0OMCg0lVX1dvtqPCJC1DjI550akA31vY8i2mE5P7k-4W1rVyU9g3FEAfSBdNsYUmt5JSzvrhzQSZVU-9_0r7isV6Idt99eewG9QFHds4MiXFxOQ=="
          },
          {
            "title": "indiatimes.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGdVa79qbMvGs-TDbttj4Aq1ywmP5L_Kx9wjzFPPDVxjMt1oCFc8g-PKp9D7yXdeYUOtHM1cVaZq6DFWhsxR31lrFx7MCFTy9vlD_csGBDgSlrKKLXXfAnsYm8__NvDRkJziRHvhT_1ug7l-wF90dvvYsyrTkPlKdZApk_j1kavzN9IqNYJltB7XQ1n3cwVkwcvdg=="
          }
        ]
      }
    },
    {
      "ticker": "ATUL.NS",
      "signal": "BUY",
      "price": 6152.5,
      "market": "IN",
      "technical_context": "Supertrend Flip (Orig SL: 5670.19, Orig TP: 7599.43)",
      "analysis": {
        "ticker": "ATUL.NS",
        "sentiment": "Bullish",
        "confidenceScore": 85,
        "validation": "Confirm",
        "reasoning": "The technical 'BUY' signal via Supertrend Flip is strongly corroborated by improving fundamentals. Atul Ltd posted robust Q2 FY26 results (Oct 2025) with a ~31-33% YoY jump in Net Profit and ~11-12% revenue growth, signaling a turnaround from previous stagnation. Analyst consensus has shifted positively, with targets ranging from ₹8000 to ₹9100, implying significant upside. The chemical sector is witnessing the end of destocking cycles, providing a favorable macro tailwind. The company remains debt-free with healthy cash flows, making the current valuation (P/E ~33x) attractive for a recovery play.",
        "fundamental_summary": "Atul Ltd reported strong Q2 FY26 numbers with Revenue at ₹1,551 Cr (+11.4% YoY) and PAT at ₹182 Cr (+30.8% YoY), driven by improved margins in Life Science and Performance Chemicals. The company is debt-free and has seen recent analyst upgrades (e.g., Motilal Oswal target ₹9100). Sector headwinds are fading as global destocking ends.",
        "catalysts": [
          "Strong Q2 FY26 earnings growth (+30% PAT).",
          "Analyst upgrades with targets >₹8000.",
          "Sector-wide recovery from 'destocking' phase.",
          "Debt-free balance sheet providing resilience."
        ],
        "tradeSetup": {
          "entryZone": "6150 - 6200",
          "stopLoss": "5670",
          "targetPrice": "7600",
          "riskRewardRatio": "1:3"
        },
        "sources": [
          {
            "title": "smifs.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGo7LiYStCjiVtlm5GSTSr94fPAK0EmGuWHSu2kIGr6VXKvPNwRZ91VLwXZ7gkFOHngKaJATuIyz6-WTv9iIv_TSUVDJvG3uFop6m_cTHqojIpT_9LPKa1pb2CIAzjbZbOcalPpGKsaP2roUT91jfYp35yh346AmG3fnDVkDubM1jzZMkCcOI3u-ywkgPA4YHYHFrUX3_fIzKi_wjDTzDG2SavDEgWls4-xnaEkiase77AQFEpPcGLyykfdAvJ07VUiyItpdYuXqTbCzmI7uEdoZs0HLJxLeeiD"
          },
          {
            "title": "stoxbox.in",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEdBTzJuYPvzAoFMxmYdspKZPOd39cFqQjyYByYsN9eQ11m41lNg0cNRnZs_Gyjx1ipPGa1FqG40iht0QJRunWeZJDjXWriYoawTsj0FGM_bATKsxW4RvP3nrllMRzh04IYuAxsBRw5r_qMbK8Zn2wRg3jkai8xRF9MZh7hmBrA4KqFyAJOMSSd"
          },
          {
            "title": "indiatimes.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHknYF4hXLOjQ_oRpTXCcdZMxWSLe1kZ7imn7UlUBbsK4KDJ_g50Rb4_gfahUvHPJr4PClg50IX8Yt6VvoV0a-xT9sezqwQxzbr8JA4Uh0jP8iomaIyk1BGREO3M7wD--1LcLG-_-iLSGW9F0uVX3pZZP_hk54jwcV_rq7FjUTp7s2cLw=="
          }
        ]
      }
    },
    {
      "ticker": "MARICO.NS",
      "signal": "BUY",
      "price": 753.0999755859375,
      "market": "IN",
      "technical_context": "Supertrend Flip (Orig SL: 714.62, Orig TP: 868.53)",
      "analysis": {
        "ticker": "MARICO.NS",
        "sentiment": "Bullish",
        "confidenceScore": 90,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal is strongly supported by fundamental tailwinds. Marico is benefitting from a robust recovery in rural demand, which has outpaced urban growth for four consecutive quarters (as of late 2024/early 2025 data). Q2 FY25 earnings showed a 20% surge in net profit and 8% revenue growth, driven by volume gains. Technically, the stock has broken out of a consolidation zone (740-750) and is trading above its 50-day (729) and 200-day (708) moving averages, confirming a structural uptrend. The Supertrend flip aligns with this breakout.",
        "fundamental_summary": "Marico's fundamentals are improving with rural volume growth growing 2x faster than urban markets. Input cost inflation (Copra/Edible Oil) has stabilized, allowing for margin expansion. The company posted a 20% YoY profit jump in its most recent quarterly results (Q2 FY25), beating estimates. Management guidance remains optimistic on double-digit earnings growth driven by the 'Project Setu' distribution expansion and premiumization of the portfolio.",
        "catalysts": [
          "Sustained rural demand recovery outperforming urban markets",
          "Upcoming Q3 FY25 earnings preview indicating volume growth",
          "Breakout above key psychological resistance at 750 INR",
          "Stabilization of raw material prices (Copra) aiding margins"
        ],
        "tradeSetup": {
          "entryZone": "750.00 - 755.00 INR",
          "stopLoss": "714.00 INR (Below 50-DMA and recent swing low)",
          "targetPrice": "830.00 - 868.00 INR",
          "riskRewardRatio": "1:3"
        },
        "sources": [
          {
            "title": "angelone.in",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFXO2aLK9IrDlJ9Sy_jQ7O3Ufu58DipcWg_cbv66SAovjdSz2KluIUEI2gJ34YLaG_0h8Du4aV6fHIhtx_E1o_WI_kwAtWj7qHRsNqvEhlbyqBsgns7Ycr1R1lWxuKVc-p8p9Fjd77DU3o85yvWSwocE33WWXV8YgewM7lW33gOGUqPiCXrOS8YTMFddydqce0iSQ=="
          },
          {
            "title": "ndtvprofit.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwrUzdOV7AWivJoNJYjJar5cfTVdfh4kXUsamVcLCiJus5N3DCwUWeeths1q4QtArl8OH2PlEPP-8-Qcf5wA5l6iJRWGvEcFDwn7I6KZjtC606UvKwvVTpu7rdrQZQKB0sHKJVXcklQXQWqW11dYikMtM2ofJOL3VwGmIRxw4eflrLD7Y0QTcQ-OTEhEibyJA="
          }
        ]
      }
    },
    {
      "ticker": "ONESOURCE.NS",
      "signal": "BUY",
      "price": 1769.5999755859375,
      "market": "IN",
      "technical_context": "Supertrend Flip (Orig SL: 1554.76, Orig TP: 2414.12)",
      "analysis": {
        "ticker": "ONESOURCE.NS",
        "sentiment": "Bullish",
        "confidenceScore": 85,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) aligns with a strong fundamental recovery narrative. OneSource Specialty Pharma (recently demerged from Strides Pharma) is witnessing a reversal from recent corrections, supported by its unique positioning as a pure-play CDMO in the high-growth GLP-1 (weight loss drug) and biologics space. Analyst coverage (e.g., JM Financial) has initiated with aggressive targets (>2000 INR), citing the 'China Plus One' tailwind and the US Biosecure Act as key drivers for order book expansion. The price reclaiming the 50-day moving average further validates the trend reversal.",
        "fundamental_summary": "OneSource Specialty Pharma is a vertically integrated CDMO specializing in complex biologics, soft gels, and injectables. It is strategically positioned to benefit from the global surge in GLP-1 agonists (e.g., Semaglutide) demand. While trailing valuations appear high (due to demerger/transition costs), forward guidance projects robust revenue growth ($160-180M for FY25) and margin expansion (~34-50% EBITDA margins in key segments). The company recently turned EBITDA positive, signaling a financial turnaround.",
        "catalysts": [
          "Surge in global demand for GLP-1 (weight loss) drug manufacturing.",
          "US Biosecure Act driving pharma contracts from China to Indian CDMOs.",
          "Recent bullish analyst initiations (JM Financial, DAM Capital) with targets above INR 2000.",
          "Technological leadership in complex injectables and device combinations."
        ],
        "tradeSetup": {
          "entryZone": "1760 - 1780 INR",
          "stopLoss": "1550 INR (Below recent swing low and support at 1630)",
          "targetPrice": "2200 - 2415 INR (Previous ATH zone and Input Target)",
          "riskRewardRatio": "1:2.5"
        },
        "sources": [
          {
            "title": "nseindia.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEYnAN064MBMX55BjjuuMYlWyPku9tfj51tv6ex1aS9CHxOnG10Urge33mNeVkf7-MvbVGiE8oWi0SUAuncC2-o4FBzZE0bYCmM8DT3fP7G__Bb3OwMvC7bgrutRmoEp17GxMbnbRng5-laOrOrR9lsMMn3qHx5"
          }
        ]
      }
    },
    {
      "ticker": "BALKRISIND.NS",
      "signal": "SELL",
      "price": 2307.300048828125,
      "market": "IN",
      "technical_context": "CE+QQE (Orig SL: 2417.20, Orig TP: 1977.61)",
      "analysis": {
        "ticker": "BALKRISIND.NS",
        "sentiment": "Bearish",
        "confidenceScore": 90,
        "validation": "Confirm",
        "reasoning": "The technical SELL signal is strongly supported by deteriorating fundamentals. Q2 FY25 results highlighted a 21% YoY drop in Net Profit and a 14% QoQ revenue decline, driven by weak export demand in Europe and the Americas (key markets). Rising freight costs due to geopolitical issues and increased US tariffs are further pressuring margins. Recent analyst downgrades (e.g., Citi, MarketsMojo) and significant underperformance relative to the Nifty Auto index validate the bearish trend.",
        "fundamental_summary": "Balkrishna Industries reported weak Q2 FY25 earnings with consolidated revenue down 1.09% YoY and Net Profit down 21.26% YoY. The company faces severe headwinds from destocking in Europe, tariff impacts in the US (>10%), and elevated logistics costs. While domestic volume is growing, it is lower margin and insufficient to offset the export slump.",
        "catalysts": [
          "Continued weak export demand from Europe and North America",
          "Margin compression due to high freight rates and US tariffs",
          "Analyst downgrades and target price cuts (e.g., Citi target INR 2350)",
          "Underperformance against the broader Auto Ancillary sector"
        ],
        "tradeSetup": {
          "entryZone": "2307.00 - 2340.00",
          "stopLoss": "2420.00",
          "targetPrice": "2100.00",
          "riskRewardRatio": "1:2.1"
        },
        "sources": []
      }
    },
    {
      "ticker": "GLAXO.NS",
      "signal": "SELL",
      "price": 2477.39990234375,
      "market": "IN",
      "technical_context": "CE+QQE (Orig SL: 2598.01, Orig TP: 2115.56)",
      "analysis": {
        "ticker": "GLAXO.NS",
        "sentiment": "Bearish",
        "confidenceScore": 85,
        "validation": "Confirm",
        "reasoning": "The technical sell signal aligns with recent fundamental weakness and broad bearish technical structure. GLAXO.NS is trading significantly below its 200-day SMA (~2850) and 50-day EMA (~2600), indicating a firmly established downtrend. Fundamental data from the September 2025 quarter (Q2) reveals a revenue decline to ₹974 Cr (down from ₹1000 Cr YoY) due to supply chain disruptions (fire at a contract manufacturing site) and seasonal headwinds. While profit remained stable, the lack of top-line growth and the stock's failure to reclaim key resistance levels justify a short position.",
        "fundamental_summary": "In the most recent quarter (Q2 FY26, ended Sept 2025), GLAXO reported a revenue dip to ₹974 Cr due to transitory GST impacts and supply constraints. Although PAT saw a marginal 2% rise to ₹255 Cr, the stagnation in the General Medicines portfolio and reliance on price hikes rather than volume growth in key segments remains a concern. The stock is underperforming the broader Nifty Pharma index.",
        "catalysts": [
          "Q2 revenue contraction due to supply chain issues.",
          "Technical breakdown below 200-day moving average.",
          "Supply constraints in General Medicines portfolio.",
          "Sector rotation out of underperforming mid-cap pharma."
        ],
        "tradeSetup": {
          "entryZone": "2470 - 2490",
          "stopLoss": "2600.00",
          "targetPrice": "2115.00",
          "riskRewardRatio": "1:3"
        },
        "sources": [
          {
            "title": "munafasutra.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFVH2C0xARWabJ-b4luLnsazRBFeCRdjX1QvNR34zSSv2LKtKfX8zz8zviZKjDCzo9OsWd62ykgncb33yO2kJ8Fy-tGkaUy9JgF12YGu5SRA7UDBLduSsvrxOkgO3xborqjLjR1Ew=="
          },
          {
            "title": "medicaldialogues.in",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEszicDcCHcEIzghwWIGlTcLsmi-C9FNeTirovQgJ04P9sjn2ey7Em0z2GZnCF0JFfwldeG4P3xEQpzvwF8ic_TfSWd1nmBMzi61nCZ0iWLA-WIlCc5gSbsi3DOFNKpEHZSgG6Cb7-6p3FR5PaV97-EoovKIObE-vp_MGOvg31fxX3dRm4Pji97ecF-xxCYIm1Vmdg-jRWhKaV_1Md83WzDenSL1o-hCNjSIQFiKNE="
          },
          {
            "title": "investing.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGhxPLTDcjWYemrZyNh3So0gqGcvr-j400TLzAaKc3f47df0NOq0ITk18ISMP-ZyW11Yd2zapAT0st72iSBlgi1hB5Z0d6LxoHTVit0kebnFv9PXFA_Wh7hVYOpZksxndm77EwdH1PQN__EXr52Zl8QX3WCi76dhU4uqA=="
          }
        ]
      }
    },
    {
      "ticker": "POONAWALLA.NS",
      "signal": "BUY",
      "price": 476.20001220703125,
      "market": "IN",
      "technical_context": "Supertrend Flip (Orig SL: 436.45, Orig TP: 595.44)",
      "analysis": {
        "ticker": "POONAWALLA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 85,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal (Supertrend Flip) is strongly supported by a fundamental turnaround. In the most recent quarter (Q2 FY26, ended Sep 2025), Poonawalla Fincorp reported a Net Profit of ₹74.2 Cr, a significant recovery from the ₹471 Cr loss in the same quarter last year (Q2 FY25). Asset quality has improved (GNPA down to 1.59% from 1.84% QoQ) and AUM growth is robust at 68% YoY. Brokerages like Anand Rathi have retained 'Buy' ratings with targets above current levels, validating the upward momentum.",
        "fundamental_summary": "Poonawalla Fincorp has successfully navigated its balance sheet cleanup from FY25. The latest Q2 FY26 results demonstrate a return to profitability (PAT ₹74.2 Cr) and aggressive AUM expansion (+68% YoY to ₹47,701 Cr). Net Interest Income (NII) rose 40% YoY. The improvement in asset quality (GNPA 1.59%) signals that the legacy stress (STPL book) is largely contained. Valuation remains attractive relative to its high growth trajectory.",
        "catalysts": [
          "Sustained AUM growth momentum (+68% YoY) driven by diversified product mix.",
          "Improvement in asset quality (GNPA reduction) boosting investor confidence.",
          "Potential sector-wide tailwinds from anticipated interest rate cuts in 2026 benefiting NBFC margins.",
          "Upcoming Q3 FY26 earnings (expected Jan/Feb) likely to confirm profitability trend."
        ],
        "tradeSetup": {
          "entryZone": "476.00 - 480.00",
          "stopLoss": "436.45",
          "targetPrice": "595.00",
          "riskRewardRatio": "1:3"
        },
        "sources": [
          {
            "title": "business-standard.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFzD0f6Z9_pjN1ffG43c80jIf1xcgwmuvblk7bWAVcG6lamgkB2I4OQNR9AdBr3Z-icjcGQZiEKIVpJ62_8qBgtd50CDpv5JXLqubYCmGUGxP2cTgR24T8HbD2_3zj9smXTgsoqYAMotEkrYMUB6mOCybnHkuwiywTt0d8t9RuvA1iAX6DdC-ALtQe_xeM41xcsPKqDo9RZ0RgzxxD9ILdIrgcWEOtFNzEahmalSbZKmKA3V0G4YIO5bVxESnY1J6RRnq4_oQ=="
          },
          {
            "title": "kotaksecurities.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFPGR75YsUzoDfFpn7R4AdleANKwa1L5rSUsUYEzOPRMuEOYSgrqI29E5eP3JBp3nEq1s4qI0ANU5f4ZvVKqjmHLjVamIpMAQ3lFsWBVYtjJWuh30hKIYkLLO18T_JMAzw9MQD8xTJTCmMDebAMSLNbCHyndhJT5vrHj7MBAdOp0h52z7uDFJ5oTsWCAvbrf62g37YsK6xa0A=="
          },
          {
            "title": "icicidirect.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHErKPPaXPtIZX5FPLv782sgoF9WynVYiRhbgQ56pNhqAu49uuzmpDrY6useCRHHuzLvdGnm5ya1RB4yovY_V14fbspKaiqIuar45l2eeRbZKJ6DcUZXtQFFKW3BlZeoxm9R-8OOvzWQdiHyur9dAeYu9mEPVJJdWvuk_kIMQ8ngA=="
          }
        ]
      }
    },
    {
      "ticker": "ABBOTINDIA.NS",
      "signal": "BUY",
      "price": 28905,
      "market": "IN",
      "technical_context": "CE+QQE (Orig SL: 27351.31, Orig TP: 33566.07)",
      "analysis": {
        "ticker": "ABBOTINDIA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 90,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal is strongly supported by fundamental tailwinds. Abbott India reported robust Q2 earnings (approx. 16% YoY Net Profit growth to ₹415 Cr) driven by its power brands and key partnerships (e.g., Novo Nordisk portfolio). Analyst consensus recently upgraded targets to the ₹33,000-₹34,800 range, citing operational leverage and margin expansion. Technically, a weekly stochastic crossover in late December 2025 aligns with the CE+QQE trend signal, suggesting a high-probability swing setup.",
        "fundamental_summary": "Abbott India continues to deliver consistent double-digit profit growth (Q2 PAT up ~15.8% YoY), underpinned by a debt-free balance sheet and superior return ratios (ROE >30%). Revenue growth is steady at ~8%, with margin expansion acting as a key value driver. The company remains a defensive fortress in the Pharma sector with high visibility on earnings.",
        "catalysts": [
          "Strong Q2 FY26 Earnings beat with margin expansion",
          "Analyst upgrades with targets up to ₹34,825 (Dec 2025)",
          "Growth in key therapies: Diabetes (Rybelsus, Ryzodeg) and GI",
          "Defensive sector rotation into Pharma amid market volatility"
        ],
        "tradeSetup": {
          "entryZone": "28,905 - 29,150",
          "stopLoss": "27,350",
          "targetPrice": "33,500 - 34,500",
          "riskRewardRatio": "1:3"
        },
        "sources": [
          {
            "title": "livemint.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGqo60TAgVMHWqu_qTqJ1htWB6TNkZiX78Gr5Jw5b6Us9H7EQBBzMcYpRWUJr9sG56E7wzI-Qqpp3sWtI2LzJh0PDOEntnseQaVKIqUf-zkLn0lkYjr9zJse8XIU2NnEXpfn0j3oMR21E8tNkYp68ruzQQWA9iXSpDaubC0KL3iLZ7hHb3DCazA"
          }
        ]
      }
    },
    {
      "ticker": "CGPOWER.NS",
      "signal": "SELL",
      "price": 647.25,
      "market": "IN",
      "technical_context": "EMA 50/200 Cross (Orig SL: 675.97, Orig TP: 561.09)",
      "analysis": {
        "ticker": "CGPOWER.NS",
        "sentiment": "Bearish",
        "confidenceScore": 75,
        "validation": "Confirm",
        "reasoning": "The technical 'Death Cross' (EMA 50 crossing below EMA 200) is corroborated by a confirmed downtrend, with the stock trading ~19% below its 52-week high of 798. Fundamentally, while Q2 FY26 (Oct 2025) profit grew ~30% YoY, it missed analyst estimates (Rev ₹2922 Cr vs Est ₹3283 Cr), triggering valuation concerns given its high P/E (>95x). The market is pricing in a correction due to the earnings miss and broader profit-booking in high-valuation capital goods stocks.",
        "fundamental_summary": "CG Power reported Q2 FY26 Net Profit of ₹286 Cr (+32% YoY) but missed revenue and profit estimates. The stock trades at a premium valuation (P/E ~95-106x), making it sensitive to any growth deceleration. While the Semiconductor (OSAT) JV with Renesas is a key long-term driver (pilot production started Aug 2025), short-term execution costs and the earnings miss are weighing on sentiment.",
        "catalysts": [
          "Technical Death Cross (50 DMA crossing below 200 DMA).",
          "Q2 FY26 Earnings Miss (Revenue and Profit below street estimates).",
          "Valuation contraction in high P/E Capital Goods sector.",
          "Long-term support from Sanand Semiconductor plant progress (Pilot started Aug '25)."
        ],
        "tradeSetup": {
          "entryZone": "645.00 - 655.00",
          "stopLoss": "685.00",
          "targetPrice": "565.00",
          "riskRewardRatio": "1:2.1"
        },
        "sources": [
          {
            "title": "upstox.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFzst4zm0iEgOairbydqtQ8GpRaoQxdz_Yr_QAWIfLXJZn_Zzjn0pZUHsrscwaRVghpfSxKLfemiy-8qvUrpeH_6SAO1DiMJZ48ZUOZBPhEmkrJZtKfEdR--GQ1UgHbyzD8-9r-mZEFx8vzWiOx7QBhkndAs62TBEKZYySxs1BO9qEdOWW9OI-gP1igpfZLT8co4VKjZ5TqyXw9XQ9hg2vOIIgoALZ6sz8AChrdMZ8josEWzcAxR150rS2IKHLSH1sv0p4dy7TrfvXEARC-5A4="
          },
          {
            "title": "newindianexpress.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEPX-9T8wmDFGH4tLsbl7dga_1HrYuhQMDrX59BNhw5-bjTQcJAaN88FueRZO25ugou5QV77t2XEaFIag1SL4YUr6JPC0z-aqcCv52_4eh1bHTrzAa8_wgJTSWubarNkymek8jRO3AJd2K2Ksd7t4orud79YOaqRKB9tkrtoUVBITH2bjcm15o-YkkCbvVWK_-lYcjqt46chW7ubctsrVU-QNeud3fV7Q=="
          }
        ]
      }
    },
    {
      "ticker": "ASAHIINDIA.NS",
      "signal": "SELL",
      "price": 963.9000244140625,
      "market": "IN",
      "technical_context": "Supertrend Flip (Orig SL: 1069.08, Orig TP: 648.35)",
      "analysis": {
        "ticker": "ASAHIINDIA.NS",
        "sentiment": "Bearish",
        "confidenceScore": 85,
        "validation": "Confirm",
        "reasoning": "The SELL signal is strongly supported by deteriorating fundamentals and insider activity. Recent Q2 FY26 earnings (Nov 2025) reported a significant 38.4% YoY decline in Net Profit and flat revenues, indicating margin pressure. Crucially, promoter holding has decreased by ~2.5% in the last quarter, a major red flag for institutional confidence. While the long-term trend (200 DMA at ~825) remains intact, the short-term structure has broken down, validating the Supertrend Flip as a high-probability correction trade towards the mean.",
        "fundamental_summary": "In the recently reported Q2 FY26 results, Asahi India Glass posted a Net Profit of ₹58.19 Cr, down 38.4% YoY, despite revenues remaining flat at ₹1,151 Cr. The company is facing headwinds from rising input costs and sluggish demand in the auto ancillary segment. Additionally, a reduction in promoter stake (-2.52%) signals potential overvaluation concerns at current levels.",
        "catalysts": [
          "Weak Q2 FY26 earnings showing margin contraction",
          "Promoter stake reduction of 2.5% in the recent quarter",
          "Slowing demand in the Indian passenger vehicle (PV) segment affecting OEM glass uptake",
          "Rising energy costs impacting float glass manufacturing margins"
        ],
        "tradeSetup": {
          "entryZone": "960.00 - 970.00",
          "stopLoss": "1015.00",
          "targetPrice": "825.00",
          "riskRewardRatio": "1:2.6"
        },
        "sources": []
      }
    },
    {
      "ticker": "HONASA.NS",
      "signal": "BUY",
      "price": 277,
      "market": "US",
      "technical_context": "CE+QQE (Orig SL: 250.96, Orig TP: 355.13)",
      "analysis": {
        "ticker": "GLAXO.NS",
        "sentiment": "Bearish",
        "confidenceScore": 85,
        "validation": "Confirm",
        "reasoning": "The signal corresponds to GlaxoSmithKline Pharmaceuticals Ltd (GLAXO.NS) on the National Stock Exchange of India (NSE). Despite the prompt's 'US Market' constraint, the ticker and price data explicitly match the Indian entity (INR currency). The SELL signal is validated by both technical and fundamental factors. Fundamentally, the company reported a 3% YoY revenue decline in Q2 due to supply chain disruptions (fire at a contract manufacturer) and seasonal headwinds. Technical indicators (Moving Averages, MACD) on the daily chart signal a 'Strong Sell' trend, with the price recently breaking down below key support at 2600. The proposed Stop Loss (2598) is well-placed above this broken support and the 50-day EMA.",
        "fundamental_summary": "In the recent Q2 results (quarter ending Sept 30), GLAXO.NS reported a 3% decline in revenue to ₹974 Cr, missing estimates due to a fire at a supplier's facility and GST transition impact. While EBITDA margins improved by ~250bps due to cost controls, the topline contraction raises growth concerns. Analysts maintain a cautious view pending supply chain normalization.",
        "catalysts": [
          "Resolution of supply chain issues (fire impact) expected in H2.",
          "Upcoming Q3 earnings results (Jan/Feb) to gauge revenue recovery.",
          "Regulatory pricing pressures (NLEM) in the Indian domestic market."
        ],
        "tradeSetup": {
          "entryZone": "2475 - 2490 INR",
          "stopLoss": "2598 INR",
          "targetPrice": "2115 INR",
          "riskRewardRatio": "1:3"
        },
        "sources": [
          {
            "title": "tipranks.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEuqJqELU6v0JwXMldvAd14emTdwukEJqWSiBcQrJn4WQczKb1BXbka-_7Pqo1Goy8Wi1Fvl2bkrNbT-TDgcewHFZHOmc078xhSFvrCJYkOroLCfQsgl5IrDEwlGX3_8NG5hOSZwTp_qnHNIzCGNFGMHzWT-16T"
          }
        ]
      }
    },
    {
      "ticker": "HUDCO.NS",
      "signal": "BUY",
      "price": 226.75,
      "market": "US",
      "technical_context": "Supertrend Flip (Orig SL: 208.64, Orig TP: 281.09)",
      "analysis": {
        "ticker": "HUDCO.NS",
        "sentiment": "Bullish",
        "confidenceScore": 85,
        "validation": "Confirm",
        "reasoning": "The signal is valid for HUDCO.NS on the National Stock Exchange of India (NSE), despite the prompt's US Market instruction. Fundamentally, HUDCO reported robust Q2 FY25 earnings with a 52% YoY jump in Net Profit and 30% loan book growth, driven by strong demand in Indian urban infrastructure. The technical entry at 226.75 INR aligns with a bounce from support (~211 INR) and analyst price targets ranging up to 300+ INR.",
        "fundamental_summary": "HUDCO posted strong Q2 FY25 results with Net Profit rising 52% YoY to ₹689 Crore and Revenue up 35% YoY to ₹2,518 Crore. The loan book expanded by 30% to ₹1.45 Lakh Crore, with management raising the FY25 loan book target to ₹1.6 Lakh Crore. Asset quality remains stable with a focus on government-backed housing projects (PMAY).",
        "catalysts": [
          "Increased Government of India spending on housing (PMAY) and urban infra.",
          "Revised loan book guidance to ₹1.6 Lakh Crore for FY25.",
          "Recent Navratna status enhancing operational autonomy.",
          "Strong Q2 earnings growth (+52% YoY Net Profit)."
        ],
        "tradeSetup": {
          "entryZone": "226.00 - 228.00 INR",
          "stopLoss": "208.00 INR",
          "targetPrice": "281.00 - 290.00 INR",
          "riskRewardRatio": "1:3"
        },
        "sources": [
          {
            "title": "scanx.trade",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGonmjjabv3SPIsd2EpaBn4ft4FKzIXSdyOX-pgvxC62pcwJPwC8-cPUZwAJqBk1IYw8RRnl5NPGpBrceyO3vOCZbeoGEQHI8W5wnJ8VUBq-8-TEX2bLZfYL9-EPb3LKCm1CDmjIEWCHFbBV_sGo10BRMSZYzoDrR_0Wj4KIfrD5OB9lfkbWvnECmqGmLnQ18Ids1Vajij33ZAnA0CI0-nqYkc9kOYRTTWMGaO9M97mCyZcobWpme-Jy6sdL2njLLGNIb99Bpk="
          }
        ]
      }
    },
    {
      "ticker": "PTCIL.NS",
      "signal": "BUY",
      "price": 19176,
      "market": "US",
      "technical_context": "Supertrend Flip (Orig SL: 16931.53, Orig TP: 25909.40)",
      "analysis": {
        "ticker": "PTCIL.NS",
        "sentiment": "Bullish",
        "confidenceScore": 90,
        "validation": "Confirm",
        "reasoning": "The signal ticker PTCIL.NS refers to PTC Industries Ltd (NSE India), not a US-listed stock, but the price (19176) aligns with its current INR valuation. Fundamentally, the company is in a hyper-growth phase driven by strategic defense and aerospace deals with Western majors like Honeywell (US) and Safran (France/US supply chain). Technically, the stock is trading near all-time highs with strong momentum, supported by a 67% YoY profit jump. The Supertrend Buy signal is validated by these fundamental catalysts.",
        "fundamental_summary": "PTC Industries is a leading Indian manufacturer of high-precision metal components for aerospace and defense. Recent financials show robust growth with Net Profit up 67% YoY. Key drivers include a long-term agreement with Honeywell Aerospace (US) for titanium castings and a deal with Safran for LEAP engine parts. The company is a primary beneficiary of the 'China Plus One' strategy in the global defense supply chain.",
        "catalysts": [
          "Long-term agreement with Honeywell Aerospace (US) for titanium castings.",
          "Strategic partnership with Safran Aircraft Engines (LEAP engines).",
          "Expansion of production at the new Advanced Materials facility in UP Defence Corridor.",
          "Q4 Net Profit growth of 67% YoY."
        ],
        "tradeSetup": {
          "entryZone": "19176 - 19400 INR (Breakout Confirmation)",
          "stopLoss": "16931 INR (Trend Support)",
          "targetPrice": "24500 INR (Analyst Extensions)",
          "riskRewardRatio": "1:2.4"
        },
        "sources": [
          {
            "title": "scanx.trade",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHDVjh3UH6x_MXDC7cX4jJqq0TtuT1vQU2d3wrVV-Rso6Ehlo4gHReflVqwuHN-3ShOV05Kx2SQoqxH2OVsDbz1y0uAGZh_bYqWWZxedg7rhFtU7rBHugmtZdAUPpv-C7dg9IlEWsECo8KYUw=="
          },
          {
            "title": "trendlyne.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEeYjjnl3SnDYaaplQvLKmJR19xazZ8-p5Xix_URoXtx_DAdkaK1kpqc2dTeBdZgTmcsPIV390t8DNuMjy7YOqKtUFf5fpXb1h8ACvNeupYoj0oxM7r6kwi66R0Mr4gTu3Xp-0hHL5TnCDfEP7d75oDRnq2V6NXWakoVX1JWSfCTtHfkGp2PPLb"
          }
        ]
      }
    },
    {
      "ticker": "ATUL.NS",
      "signal": "BUY",
      "price": 6152.5,
      "market": "US",
      "technical_context": "Supertrend Flip (Orig SL: 5670.19, Orig TP: 7599.43)",
      "analysis": {
        "ticker": "ATUL.NS",
        "sentiment": "Bullish",
        "confidenceScore": 85,
        "validation": "Confirm",
        "reasoning": "The technical Supertrend flip is supported by robust fundamental tailwinds. Atul Ltd reported strong Q2 FY25 earnings with a 31% YoY increase in Net Profit (PAT) to ₹182 Cr and 11% revenue growth, driven by volume recovery in Life Science and Performance Chemicals. The company is in a capital expansion phase, with a new Liquid Epoxy Resins plant (50ktpa) set to commission in FY25, providing visible revenue visibility. Analyst consensus aligns with a 'Buy' rating, projecting revenue/PAT CAGR of 13%/39% through FY27. The stock is technically breaking out of a consolidation phase, validating the momentum signal.",
        "fundamental_summary": "Atul Ltd is a diversified chemical company benefiting from the 'China Plus One' global sourcing shift. In Q2 FY25, it delivered a 31% YoY profit jump, improving margins to ~15%. The balance sheet remains strong with negligible debt, supporting ongoing capex without financial stress. Valuations are reasonable relative to historical averages given the renewed growth trajectory.",
        "catalysts": [
          "Commissioning of 50ktpa Liquid Epoxy Resins plant in FY25",
          "Continued recovery in global agrochemical demand",
          "Sustainable margin expansion from recent lows"
        ],
        "tradeSetup": {
          "entryZone": "6140.00 - 6180.00",
          "stopLoss": "5670.00",
          "targetPrice": "7599.00",
          "riskRewardRatio": "1:3.0"
        },
        "sources": [
          {
            "title": "economictimes.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGg0wYSATsyG-12X89trIpL9246DcRYGjNt0zPlljK0OWfFmeGkXPfUKE7gs_SXlaFshWTDz3zaA3A20MDLQmD8xiZmMvon7dB428DtTi8z6i_eawJvWPw3It0orYabVJaOemU3JWicOqbJIDOLHiyyKO-aA10vBA6Lof58bXJekM9YOEoJWSY1XZu0ZpvkW757RIiMVKqGwvG2lw3t1QyYb8En3Iu0SRzxGnDcpFtIBScBKHQfkBkaNCptli1-LMwvDV-UxorlyKOWzN6l15EKKOEH9OByxn1HcHdQptRtTc965sqkL24Ajoo="
          }
        ]
      }
    },
    {
      "ticker": "MARICO.NS",
      "signal": "BUY",
      "price": 753.0999755859375,
      "market": "US",
      "technical_context": "Supertrend Flip (Orig SL: 714.62, Orig TP: 868.53)",
      "analysis": {
        "ticker": "MARICO.NS",
        "sentiment": "Bullish",
        "confidenceScore": 85,
        "validation": "Confirm",
        "reasoning": "Despite the user's template indicating a 'US Market' context, MARICO.NS is a prominent Indian FMCG stock (Marico Limited). The signal is confirmed based on strong fundamental tailwinds and technical alignment. The company reported robust Q2 FY26 revenue growth of 31% YoY and a 7% recovery in domestic volume, signaling a turnaround in rural demand. While operating margins softened to 16.1% due to input inflation (copra prices), the volume trajectory is positive. Technicals show the stock trading near 52-week highs (765 INR) with a Supertrend flip indicating bullish momentum. Analyst consensus remains strong with price targets revised upwards to the 820-875 INR range.",
        "fundamental_summary": "In the recent Q2 FY26 earnings (Nov 2025), Marico delivered 31% YoY revenue growth and 8% PAT growth. Domestic volume growth hit a multi-quarter high of 7%, while the international business grew 20% in constant currency. Management commentary highlights a recovery in rural sentiment and steady urban demand. Margin pressure from high copra prices is viewed as transitory, with expectations of improvement in H2.",
        "catalysts": [
          "Continued recovery in rural FMCG demand in India.",
          "Strong double-digit growth in international markets (Bangladesh, Vietnam).",
          "Potential easing of copra prices improving gross margins in upcoming quarters.",
          "Analyst upgrades with targets raised to ~850-875 INR."
        ],
        "tradeSetup": {
          "entryZone": "750.00 - 755.00 INR",
          "stopLoss": "714.00 INR (Below Supertrend Support)",
          "targetPrice": "825.00 - 850.00 INR",
          "riskRewardRatio": "1:2.1"
        },
        "sources": [
          {
            "title": "business-standard.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE_PGQUrUDQrrosEsRrjOFOicdXWq4VGIslkd0VpEXyGv0GXV26zym-PleapykfnYZil3O3PC2dV24cRdMt99S3GMH5PmvfmXgg9dQwNAhwFt2qvQjNMJP4uSAwpp44kBNwUTX0ZRGK6LQ="
          },
          {
            "title": "angelone.in",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE_wiU4x7wA6WtTjT1o_WNXGtvYwGGs3yj2GpK6j2Y9sIWKXd-qiRP0DW5oqz-5O63OgOjWMQodvtEY_lpqGHXaksnBYoj7jym_igdjoDffmwqGRwJIO_u5Cqy6gBiznL1lyIEVjmLm_-2d3gkDUwGetF1R0JUQMeR6dOO0QyvMnkitjZxfYldUA4F0uK9o31pR24qipHC_hWajJ1D2eyyPRhab_BNGLT18FPpqoLUEjAQSuJJdTnxkg6YhDQ=="
          },
          {
            "title": "economictimes.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHq2P0cpI9ls-9n69xv9HMQ7cuu9kxQwEOW2rnpAeU2jP-_sPsfpLigWkYRi8SQQ4EBlDeOzF6UX6p2Cg8SLFAoc7N4tGsE75Nh_S8RjBFqLpOiXuCNCeViz_k_yogncVmaXto8CGi8hwBMnRNTRxt2_0Mh9t0UfRZqdsHHZgfSQqnqgsxYPKPQQba4v1zQqoEiEvzjWYEdh_NvL8ag3Ra7a-ROiBPPzUjHAjlqn8RypZGk8es="
          },
          {
            "title": "business-standard.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGBndQGo-u2b5VXFGmfWFWP2SWBe1ITjHhb0qpvccKznF2Ztf9p9PcDg5bXlRXaKWSY6Fb0-zhv1YY2LfvWZoiWYLy2q8bMHRW8IyUwMpAyfWxRam5mnsPNnjWKOKnALPqh_24l4Ehok9W9KMQpMKtiKKl1rjCun9F1k2vu08p8qaIq9cbdbSrs0yumN0gl-xGi3qMMtaMjOO40qQav8OPsi-ZeSBgKYZ3MkCVBdz6HT9X2ZnBdHKz9PerDJB7jltBhy62wpDiC7OZcDAsu5jo5uBWPKzTpEFmckLOUcXchmCc9nzJr52FSqis6V8Ih3w=="
          },
          {
            "title": "marketscreener.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH3zZ2o2iJtZO_Zwa4qyn0JwsJxqQrAAxJ5ipbmYDk_3GqgcRB5DElng3xr1Iz43B4r1jy0RkfPsErH_wUa0HY4_aX_ENSZU8DKDQ2vaE5j_hNJebtQprU3zvW-qQihirKOeG1lCXEfTq0MB9-1gsRs3BRqN0pZaTn8lTzP6w4gVoqA0SQkg4Q="
          }
        ]
      }
    },
    {
      "ticker": "POONAWALLA.NS",
      "signal": "BUY",
      "price": 476.20001220703125,
      "market": "US",
      "technical_context": "Supertrend Flip (Orig SL: 436.45, Orig TP: 595.44)",
      "analysis": {
        "ticker": "POONAWALLA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 85,
        "validation": "Confirm",
        "reasoning": "The technical Supertrend Buy signal is supported by strong fundamental tailwinds, including robust AUM growth (+40-50% YoY) and a turnaround to profitability in recent quarters (Q2 FY26). The stock is outperforming the benchmark index. Note: This ticker (POONAWALLA.NS) trades on the NSE (India) in INR, contrary to the 'US Market' context provided; analysis reflects Indian market data.",
        "fundamental_summary": "Poonawalla Fincorp has demonstrated impressive growth, with recent reports indicating a 40%+ increase in Assets Under Management (AUM) YoY and improved asset quality (low GNPA). The company has successfully pivoted to a tech-led consumer and MSME financing model following the divestment of its housing finance arm. Recent quarterly results show a return to net profitability compared to prior year losses.",
        "catalysts": [
          "Strong Q2 FY26 Earnings showing turnaround to profit",
          "Continued AUM expansion driven by digital-first strategy",
          "Potential credit rating upgrades due to improved financial health",
          "Sector rotation favoring high-growth NBFCs in India"
        ],
        "tradeSetup": {
          "entryZone": "470.00 - 478.00 INR",
          "stopLoss": "436.00 INR",
          "targetPrice": "570.00 - 595.00 INR",
          "riskRewardRatio": "1:2.8"
        },
        "sources": [
          {
            "title": "marketsmojo.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH40ts5wwYCPfwqr9vk2IOv8VWcHuyhuGS3Vt7_O1M-RgkGf2V3rW6ano6_ExG-9TPkyN6j3yTtHvhn00jGM7eR_WVuE_lw8zEkKyzylecf9uaqoDlf7hFHBgqFQ2jmQPNhvCD_e0Wnl3W9Q844s_ycEl2VfcD3uhhuNgQ5LuMRCsbdUMoV8wl2u3nItk5Khqmj_ViTIVldWi6x8tklu1SVbjvsSfy_JlWHuXZv5URgqLDNft57Fky6AdWk3vsWAjGhWh4C9YWBuA5YWLd3tqfabhjrjtee9g=="
          },
          {
            "title": "topstockresearch.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGOsy0CsEbsjoc7cYli97sg8LNi4g5uuyuFpU7ZZh7kXjz_xaPIPGujqibPkpchlNywVtSnJOXF6ueIj1yOUoXKNsnP-yrHzKeBv_YMO0MhMF8txTXBBlqeDXAe-1DKaf423uhVlw66br9_u41AdZjazGXeyajWC8mkLI6447F9HLI="
          },
          {
            "title": "livemint.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHIc6uME0ra-owzrpkAXGeTYhdJjSgBpqYwHwLwfDJUGFrtBKzAj1_pnrNVpgx0V2-r3vWh20Fqn6YAyOkyE8neKfMXKHX7iT5cJMb80r7Ju6LGXeqgz-jwR3mZndDe99LAt0sp3feLErmAUSEJBvnyB-k0Nnl0QIsQ3OnprvkuI6LRDZHcJFVe9Dnyzskor4mukHhejxT_KFhwVdObkPNLvTZgWyLvlK2KEthU8kLh_PbvDL3Bh0rOzkWoZ6rpZkglTZLeb-wG"
          },
          {
            "title": "icicidirect.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFHaqKkfquQMxcMNKtv7cLkK1YHpd4_wJuvBQMvnr9JdRsYRR47HnjG6C8JCoJ7lbM-w-aSj2-OviQpwmVgOFoDoFak0SCzt0lQ8tyMucMYRGHuV5ZC3uoAKMBqDwPEYSbWJGiCiNxQu2nrlDmBh0Uuq28kQ6_fSU1in21r5f56hasdgXEInng_qM21"
          }
        ]
      }
    },
    {
      "ticker": "ABBOTINDIA.NS",
      "signal": "BUY",
      "price": 28905,
      "market": "US",
      "technical_context": "CE+QQE (Orig SL: 27351.31, Orig TP: 33566.07)",
      "analysis": {
        "ticker": "ABBOTINDIA.NS",
        "sentiment": "Bullish",
        "confidenceScore": 85,
        "validation": "Confirm",
        "reasoning": "The technical BUY signal is strongly supported by fundamental tailwinds. Abbott India recently reported a robust Q2 with a 16% YoY jump in net profit and significant margin expansion (EBITDA margin improved to 28.6%). As a debt-free subsidiary of the US healthcare giant Abbott Laboratories, it benefits from strong parentage and a defensive rotation into high-quality pharma stocks during volatile market conditions. The current price consolidation offers a favorable entry point aligned with the CE+QQE signal.",
        "fundamental_summary": "Abbott India delivered strong Q2 earnings with Revenue up 7.7% to ₹1,757 Cr and Net Profit up 16% to ₹415.3 Cr, driven by operational efficiencies and volume growth in key therapeutic areas. The company maintains a premium valuation due to its debt-free balance sheet, high return ratios (ROE ~35%), and consistent dividend history. Its connection to Abbott Labs (NYSE: ABT) provides a continuous pipeline of innovative products in diagnostics and nutrition.",
        "catalysts": [
          "Q2 Earnings Beat: 16% YoY Profit Growth",
          "Margin Expansion: EBITDA margins improved to ~28.6%",
          "New Product Launches: Introduction of new diagnostic and nutrition products in the Indian market",
          "Defensive Sector Rotation: Institutional inflows into high-quality Pharma/FMCG stocks"
        ],
        "tradeSetup": {
          "entryZone": "28,900 - 29,100 INR",
          "stopLoss": "27,350 INR",
          "targetPrice": "33,500 INR",
          "riskRewardRatio": "1:2.8"
        },
        "sources": [
          {
            "title": "angelone.in",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEjiRyWWg4RJ2sJabQz0cTsq1LgoCSvXP0YFVA4uzCe_r6Cy6QSlnOnPPkh_RZkrUxpKcx_Oa0VyRb8vcZA9xtkrbGtToTe3tD3DbB5AQ502tiR00iqu1B9-Bj1H3LgV_uG9_AJYATAAbysEnNxyXXpq2ptPIrmQ8TrTMFJGa0-WoMS8wSzCNw_vd5b1Xg35Fp2VpY_WtndqgD6KmtaJJxWHwTiGG6Lvq1Do97niQGKvg=="
          },
          {
            "title": "screener.in",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGSMoOy7fpy7IRqPzc9AovrsogjEX9cG2tmhdOcOAK0dXgOZPNiyHXoAK6Qt9cRoRxaMfBrIHyWDcqhwJ-l5WS4oEJHGv1l8UnJbSeRCAo_RzL6VUvRs1FJvuxuhb9WgL003X5_m6A="
          }
        ]
      }
    },
    {
      "ticker": "CGPOWER.NS",
      "signal": "SELL",
      "price": 647.25,
      "market": "US",
      "technical_context": "EMA 50/200 Cross (Orig SL: 675.97, Orig TP: 561.09)",
      "analysis": {
        "ticker": "CGPOWER.NS",
        "sentiment": "Bearish",
        "confidenceScore": 85,
        "validation": "Confirm",
        "reasoning": "The technical SELL signal is supported by fundamental weakness and a 'Death Cross' (EMA 50 crossing below EMA 200). CG Power recently reported Q2 earnings that missed both revenue and profit estimates, with its Industrial Systems segment contracting by 1.8%. Despite a 32% YoY profit rise, the stock's premium valuation (P/E >90x) leaves little room for error. The high execution risk associated with the new semiconductor (OSAT) facility capex, combined with broader market profit-taking, validates the downside momentum.",
        "fundamental_summary": "In Q2 FY26 (Oct 2025), CG Power reported revenue of ₹2,922 Cr (+21% YoY) and Net Profit of ₹286 Cr (+32% YoY), both missing analyst estimates of ₹3,283 Cr and ₹313 Cr respectively. While the Power Systems segment grew, the Industrial Systems segment declined. The stock trades at a lofty valuation, making it sensitive to the earnings miss.",
        "catalysts": [
          "Q2 Earnings Miss: Revenue and Profit fell short of street estimates.",
          "Technical Breakdown: EMA 50 crossed below EMA 200 (Death Cross).",
          "Segment Weakness: Industrial Systems revenue declined 1.8% YoY.",
          "Valuation Concerns: High P/E ratio (>90x) prompts profit booking."
        ],
        "tradeSetup": {
          "entryZone": "647.00 - 655.00",
          "stopLoss": "676.00",
          "targetPrice": "561.00",
          "riskRewardRatio": "1:3"
        },
        "sources": [
          {
            "title": "scanx.trade",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHGyDs5qm_GjRCK_HjuZlLVBgs3YEgqa3dWQ7DP0tWTigWHr8e77V6KZSmtsvVUuYtUUVKLFzlqun0iutYjB6qkzdi0j7ifY1MyCTxngRpbf7pXhnzRsqKBZUZO8wRoV2a7Z2OoZ7HVKElm7XC_67PMn_FMfQtf8rhAVcrxVZrd6dsKl4Ym1Ieo-HvsGupl0PF6x-hpjvrboEeVzJkIS7XzkmYmiKP0awqfdFAnUkCXPPk="
          },
          {
            "title": "investing.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFWDiSeMTpuXVMR5IIV-21hK7yvN1flYOez-Z2FM8wgGyPhe_vjk7mxUYQKxnZDy9YZTU9A1-SUzIWp6ojecEXlm1oeXR2nDZRPnGd8XTjgrg-4scZEfELDeP3bRKT4fzsGFoZoDx0V9IIspVFaWZ8ZwvFwBxTQ"
          },
          {
            "title": "companiesmarketcap.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGM1IHMDtknFhMfl4mC1KrbXfWeUjMjQKwXlwm8Zss1Ru_jjMUhMokmCcxeKpIIL7vY5FdIFZJX0XyDx9QpFrzJF99_4ajoB3W9v627eJ2XZ0tZWEh41bB5yCh0QHKFPgZSN9pkOvhR8ZZreA=="
          }
        ]
      }
    },
    {
      "ticker": "ADANIPORTS.NS",
      "signal": "SELL",
      "price": 1454.4000244140625,
      "market": "US",
      "technical_context": "Supertrend Flip (Orig SL: 1536.01, Orig TP: 1209.58)",
      "analysis": {
        "ticker": "ADANIPORTS.NS",
        "sentiment": "Bearish",
        "confidenceScore": 85,
        "validation": "Confirm",
        "reasoning": "Despite strong Q2 FY26 operational growth (Revenue +30%, PAT +27%), the stock faces a technical breakdown (Head & Shoulders pattern) and significant overhang from US legal challenges. The US DOJ indictment and SEC charges (Nov 2024) regarding alleged bribery continue to dampen foreign institutional sentiment, acting as a valuation ceiling. The current 'SELL' signal aligns with a 'sell the news' reaction post-earnings and a broader technical reversal from the 2025 rally.",
        "fundamental_summary": "In Q2 FY26 (Nov 2025), Adani Ports reported robust numbers with Consolidated Revenue at ₹9,167 Cr (+30% YoY) and Net Profit at ₹3,120 Cr (+29% YoY). However, the lingering impact of the US Department of Justice (DOJ) and SEC bribery indictments (from late 2024) creates a persistent governance risk discount, deterring aggressive buying at these elevated levels despite the operational beat.",
        "catalysts": [
          "US DOJ & SEC Bribery Indictment Fallout (Legal Overhang)",
          "Technical Breakdown: Head & Shoulders Formation",
          "Profit taking following 18% rally in 2025",
          "Global risk-off sentiment impacting Emerging Markets"
        ],
        "tradeSetup": {
          "entryZone": "1450 - 1460 INR",
          "stopLoss": "1536 INR",
          "targetPrice": "1210 INR",
          "riskRewardRatio": "1:3"
        },
        "sources": []
      }
    },
    {
      "ticker": "ASAHIINDIA.NS",
      "signal": "SELL",
      "price": 963.9000244140625,
      "market": "US",
      "technical_context": "Supertrend Flip (Orig SL: 1069.08, Orig TP: 648.35)",
      "analysis": {
        "ticker": "ASAHIINDIA.NS",
        "sentiment": "Bearish",
        "confidenceScore": 90,
        "validation": "Confirm",
        "reasoning": "The SELL signal for Asahi India Glass (ASAHIINDIA.NS) is strongly supported by both technical and fundamental factors. Fundamentally, the company reported weak Q2 FY26 earnings (Nov 2025) with Net Profit declining ~38-40% YoY to ₹58.19 Cr due to rising interest expenses and margin compression. The debt-to-equity ratio has deteriorated, and the company recently raised capital to manage debt, indicating financial stress. Technically, the stock is trading below key moving averages (including the 200-day MA around 998) and momentum indicators like MACD and RSI confirm a bearish trend. The 'Supertrend Flip' aligns with the breakdown of support levels following the earnings disappointment.",
        "fundamental_summary": "In Q2 FY26 (reported Nov 2025), Asahi India Glass saw Revenue stagnant at ₹1,151 Cr (-0.56% YoY) and Net Profit plunge ~38% YoY to ₹58.19 Cr. Margins contracted significantly to ~4.87% driven by higher interest costs (up sharply to ₹59 Cr) and input cost inflation. The company holds a high debt burden, necessitating a recent ₹1,000 Cr QIP for deleveraging.",
        "catalysts": [
          "Q2 FY26 Earnings Miss: ~40% drop in Net Profit.",
          "Rising Debt Servicing Costs: Interest expense spike hurting margins.",
          "Sector Headwinds: Moderate growth forecast for Indian Auto Ancillaries amid global freight/supply chain issues.",
          "Technical Breakdown: Price crossing below 200-day Moving Average."
        ],
        "tradeSetup": {
          "entryZone": "960.00 - 970.00 INR",
          "stopLoss": "1015.00 INR",
          "targetPrice": "880.00 INR",
          "riskRewardRatio": "1:2.1"
        },
        "sources": [
          {
            "title": "investing.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGxEFIQ1xb2ANe_PJsQbQYZo-RnIAvflDUVbc7YRtbIebZcrarVCCEVQHdKsOXe2ct2T1FMsMRTdfD3ClEhfFEp5YTUYR1SfjLmFsqjUrbCBCpqhsKUFaBOuX6BVkJdZHZAjFlXKjQ7rk5-FYrR5XKzFSqkNZPeifA="
          },
          {
            "title": "hindustantimes.com",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHFupdgZOz0BXYhhCc-TlNUWPghnEZnZebEBKW13zC0DLzCsey8E5SGFwb9e0MEnOkvQ5NrtA1HDb9H25dgfAN1wYqUQ5hb9x-dhXsKgfFglwqWEl4UTEJFYIZrb4kvXyznPJgVZpuDlEkA5-XQ2pT58BELTq0TTp8req3JB2yFCUkqb-u3VJSaxmC5TRQ8Fya56ImQUyvCzk9DY8ySsYEJRUTZml58lOOYDfJrCcLLuzttMtwGIDjktt-G_PbpjZ-XkDU7Btj4"
          },
          {
            "title": "scanx.trade",
            "uri": "https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGLz5iLQGD0Sl-ZmIWjKGGiYJe1aKYRKzvUvlAodqnrirMJY-Usunq-aYe0rN6XAQmuf8rnfYVys6WEiFQ9FYS8TxOUC6khrM49BgS2s4R49wOiqvPV0xuA-pN_4HXZNLOeIQ9QyfzjtNGIEoE6_9Idu2sQi8I2kkPyUCR4O2dVxM8Itl8wmD84NBJJ_rAQDEa3pdPvLg8qY1fA1UiK8u_tTdq-5RBkKkIVYuAuVkFxUJqVoA=="
          }
        ]
      }
    }
  ]
}